Section 14. Designation of Orphan Drug.— The DOH, motu proprio or upon application by any interested person, and with the recommendation of the RDTWG, may designate any drug or medicine indicated for use by patients afflicted with any of the rare diseases as an orphan drug. Within one hundred twenty (120) days from the effectivity of this Act, the DOH shall publish a list of orphan drugs for these rare diseases.